Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-09-10

Last Posted Date: 2013-08-12

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 100

Registration Number: NCT00526734

Locations: 🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇵🇱
Institute of Haematology and Blood Transfusion, Warsaw, Poland
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium

and more 1 locations

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2

Terminated

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Melphalan
Drug: Thymoglobulin

First Posted Date: 2007-09-03

Last Posted Date: 2013-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00523809

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Phase 2

Completed

Conditions: Primary Systemic Amyloidosis
Light Chain Deposition Disease

Interventions: Drug: bortezomib
Drug: dexamethasone
Drug: melphalan
Genetic: microarray analysis
Other: flow cytometry
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment

First Posted Date: 2007-08-27

Last Posted Date: 2023-12-22

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00520767

Locations: 🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 4 locations

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Biological: sargramostim
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-08-27

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT00521014

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Melphalan
Drug: Thalidomide
Drug: Prednisone

First Posted Date: 2007-07-26

Last Posted Date: 2014-05-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 502

Registration Number: NCT00507416

Locations: 🇺🇸
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
🇺🇸
S. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
🇺🇸
Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States

and more 219 locations